What is the success rate for treatment?
Key Points
Keytruda (pembrolizumab) is a prescription medicine used to treat many different types of cancers, including solid tumors and blood cancers. It might be used alone or in combination with other medicines for advanced cancers, cancers that have spread in the body, or cancers no longer responding to treatment.
Keytruda is used for cancers such as:
In clinical studies of the cancer types that Keytruda is approved to treat, researchers studied groups of patients to better understand how well Keytruda works and the side effects. These study results can help to inform you and your doctor which treatment might work best for you. Ask your doctor about the success rates from the Keytruda studies that evaluated your specific type of cancer.
As an example, three types of cancer approved by the FDA for Keytruda treatment are non-small cell lung cancer, advanced melanoma (a serious form of skin cancer), and bladder cancer. Here are success rates from some of these studies.
Advanced non-small cell lung cancer (advanced NSCLC)
When used as an initial therapy, Keytruda + chemotherapy has been shown to help patients with advanced nonsquamous NSCLC live longer than using chemotherapy alone.
In one study, half of the patients receiving Keytruda + chemotherapy were alive without their cancer spreading, growing, or getting worse at 8.8 months, compared to 4.9 months for patients treated with the chemotherapy regimen alone. Cancer did not progress in 40% of patients receiving Keytruda + chemotherapy compared to 19% of patients receiving chemotherapy alone.
Advanced melanoma (skin cancer)
Keytruda has also been studied in advanced melanoma, a skin cancer that cannot be removed by surgery or has spread in your body (metastatic). It can also be used after surgery to lower the risk of cancer coming back. Keytruda can help shrink tumors and help you live longer.
Researchers found that Keytruda can help patients with advanced melanoma live longer when compared to treatment with ipilimumab (brand name: Yervoy), another immunotherapy drug (KEYNOTE-006).
Advanced bladder and urinary tract cancer (urothelial carcinoma)
Keytruda was evaluated in a clinical study of patients with urothelial cancer who had previously received a platinum-based chemotherapy regimen (KEYNOTE-045). For the patients receiving Keytruda, the chemotherapy had either never worked or stopped working. Overall, patients receiving Keytruda lived longer than those receiving chemotherapy.
Bottom Line
This is not all the information you need to know about Keytruda (pembrolizumab) for safe and effective use. Review the full Keytruda information here, and discuss this information and any questions you have with your doctor or other health care provider.
Related medical questions
- What are monoclonal antibodies?
- How long does it take for Keytruda to work?
- What is the success rate for treatment?
- What is the difference between Opdivo and Keytruda?
- Can you take prednisone with Keytruda?
- Is it covered by Medicare / Medicaid?
- Is Xalkori the same as Opdivo or Keytruda?
- Pembrolizumab vs. nivolumab: how do they compare?
- How are Inlyta and Keytruda used in kidney cancer?
- What are monoclonal antibodies?
- How long does it take for Keytruda to work?
- What is the success rate for treatment?
- What is the difference between Opdivo and Keytruda?
- Can you take prednisone with Keytruda?
- Is it covered by Medicare / Medicaid?
- Is Xalkori the same as Opdivo or Keytruda?
- Pembrolizumab vs. nivolumab: how do they compare?
- How are Inlyta and Keytruda used in kidney cancer?
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions